Navigation Links
Stronger Backing for Drug-Coated Stents

New research proves drug-coated stents effectively combat death, heart attack and repeat procedures in the real world.//

A new study from researchers in the Netherlands indicates that patients in clinical trials of drug-coated stents represented a very select group of the total population. This new study takes a closer look at the effects of drug-coated stents on real-world patients, patients the researchers say tend to be older and sicker than those selected for clinical trials.

The study included more than 500 patients with previously untreated blocked arteries who were treated with drug-eluting stents. An additional 450 patients with comparable blockages were treated with bare metal stents. Sixty-eight percent of the patients in this trial did not meet the selection criteria of previous clinical trials.

Results of the one-year study show 9.7 percent of patients who received drug-eluting stents had a major adverse cardiac event, compared with 14.8 percent of patients treated with bare metal stents. Only 3.7 percent of patients with drug-eluting stents experienced renarrowing of the treated vessel, a common complication that leads to corrective procedures. However, 10.9 percent of patients with bare metal stents required repeat procedures to correct renarrowing of the artery.

Lead investigator Patrick W. Serruys, M.D., Ph.D., from Erasmus Medical Center in the Netherlands, says, “The treatment effects -- particularly the reduction of re-interventions -- were similar across very different subgroups of patients.” He says drug-eluting stents are the next major step in interventional cardiology.

In an accompanying editorial, David P. Fason, M.D., from the University of Chicago, says the research results “go a long way in re-assuring the practitioner that drug-eluting stents are in fact safe and effective in a wide variety of patients undergoing ‘real world’ angioplasty.” He concludes that the next step shoul d be a mandatory registry established by the Food and Drug Administration to report problems.


'"/>




Related medicine news :

1. Health Care Ties To Get Stronger Between India And Britain
2. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
3. Stronger Doses Fewer Administration for Breast Cancer
4. Stronger Quadricep Controls Knee Osteoarthritis
5. Old Indian Advice Has A Scientific Backing Now!
6. Fury over Backing of Health Shake-up
7. Failure of Drug-Coated Stent
8. Drug-Coated Stent
9. Drug-Coated Stents – Proven to be More Effectiv
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Drug-Coated Stents – Proven to be More Effectiv
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... Massachusetts (PRWEB) , ... February 10, 2016 , ... ... models to effectively measure change in their patients. Research shows that the Goal ... methods. To help therapists overcome this challenge and learn more about the Goal ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... has been awarded the prestigious Distinguished Emerald Club of the World award, as ... BoardRoom magazine, one of the most respected trade publications serving private clubs. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has ... state still face a lot of restrictions as to where they can smoke pot. ... personal use” and that cannabis “may not be consumed openly or publicly.” , Given ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: